ClinicalTrials.gg
CompletedNCT05832151Updated Nov 5, 2026

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

A Phase 2 interventional study of CIN-102 Dose 15mg or 10mg and Placebo in Diabetic Gastroparesis, sponsored by CinDome Pharma, Inc.. Completed at 100 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
7th of 136
382 · median 36
Started
2023
with 10 others
Phase 2
38 of 184
none open now
Registered
150th of 184
by date
Lead sponsor
4 of 184
CinDome Pharma, Inc.

Among the 184 studies in Gastroparesis with a site in United States, this one is the 7th largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2023, is one of 38 in phase 2, and was the 150th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.

The main questions it aims to answer are:

  • To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo
  • To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo

Participants will go through the following schedule:

  • Screening period (1-2 visits)
  • Lead-in period (1 visit)

    • Will complete a Gastric Emptying Breath Test (GEBT)
    • Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation
  • 12-week treatment period (7 visits)

    • Study drug taken twice daily by mouth
    • Will complete daily diaries and other PROs as described in protocol
  • 1 week follow-up (1 visit)

Researchers will compare the effects of the following treatments:

  • Drug- CIN-102 Dose 15 mg or 10 mg
  • Drug- Placebo
03

Conditions studied

  • Diabetic Gastroparesis

Keywords

  • Gastroparesis
  • Diabetic gastroparesis
  • Gastrointestinal disease
  • Delayed gastric emptying
  • Digestive system diseases
  • Nausea
  • Vomiting
  • Stomach
  • Dopamine receptor antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Is a male or female ≥18 years of age;
  • Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria;
  • Has a current diagnosis of diabetic gastroparesis defined by the following:

    1. Persistent gastrointestinal symptoms that in the opinion of the Investigator are consistent with gastroparesis within 6 months prior to Screening; AND
    2. Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT), scintigraphy, or manometry.
  • (BMI) between 18 and 49 kg/m2, inclusive;
  • Glycosylated () level \<10% at Screening;
  • If receiving treatment with GLP-1RA, may be considered for the study if all of the following criteria are satisfied:

    1. The GLP-1 RA has been prescribed for the management of diabetes and not specifically for weight loss/weight management;
    2. Has been on a stable dose of GLP-1RA for a minimum of 3 months before Screening and is anticipated to sustain the same dose during GEBT and throughout the study;
    3. Is tolerating the GLP-1RA well based on Investigator's judgment;
    4. None of the study-qualifying signs/symptoms of gastroparesis are solely attributable to the use of GLP-1RA; and
    5. The symptoms of gastroparesis preceded the initiation of GLP-1RA therapy.
  • Willing to washout from ongoing treatment for gastroparesis.

Key Exclusion Criteria:

  • Has known cause of gastroparesis other than diabetes (eg, idiopathic gastroparesis and/or gastroparesis attributed to surgery, viral illness, cancer, scleroderma, or other neurologic disorder);
  • Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition;
  • History or evidence of arrhythmia;
  • History of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy, fundoplication, gastrectomy, vagotomy, or bariatric surgery;
  • Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression;
  • Pyloric injection of botulinum toxin within 6 months of Screening;
  • Positive test for drugs of abuse;
  • Has a known allergy to eggs or spirulina;
  • Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
382 participants (actual)

Study arms

  • Experimental
    CIN-102: Dose 15mg or 10mg

    CIN-102, Dose 15 mg or 10 mg, twice daily for 12 weeks

    Drug: CIN-102 Dose 15mg or 10mg

  • Placebo comparator
    Placebo

    Placebo for CIN-102, twice daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugCIN-102 Dose 15mg or 10mg

    Drug pages: CIN-102 · Deudomperidone

    2 capsules twice daily for 12 weeks

  • DrugPlacebo

    2 capsules twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale scores and the Vomiting subscale scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe)

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Secondary outcomes

  1. Incidence of clinically significant changes, in the Investigator's opinion, in laboratory parameters, physical examination findings, 12-lead ECG parameters, weight measurement.

    Time frame: Over the 12-week Treatment Period

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Over the 12-week Treatment Period

  3. Incidence of treatment emergent Serious Adverse Events (SAEs)

    Time frame: Over the 12-week Treatment Period

  4. Incidence of TEAEs leading to premature discontinuation of study drug

    Time frame: Over the 12-week Treatment Period

  5. Incidence of treatment-emergent marked laboratory abnormalities.

    Time frame: Over the 12-week Treatment Period

  6. Percentage of responders who demonstrate an average ≥0.5 reduction from baseline on the ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period

  7. Percentage of subjects achieving a ≥30% reduction from baseline on a composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period

  8. The percentage of symptom-free days in the ANMS GCSI-DD Total Score, a composite of the Nausea Sub-Scale and Vomiting Scores, and Sub-Scale Scores

    Symptomatic days defined as \>mild (ANMS GCSI-DD scores \>2)

    Time frame: Over the last 2 weeks of the 12-week Treatment Period

  9. The relationship between ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) over the 12-week Treatment Period;

    Time frame: Over the 12-week Treatment Period

  10. Percentage of subjects with a history of a lack of response or who could not tolerate metoclopramide therapy or other prokinetics, who demonstrate a >30% reduction from baseline on a composite score

    Composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

  11. Effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline

    Based on the average ANMS GCSI-DD Total and Sub-Scale Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

  12. The change in the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores among subjects receiving glucagon-like peptide-1 receptor agonist (GLP-1RA)

    Time frame: Over the 12-week Treatment Period as compared to baseline

  13. The percentage of responders among subjects receiving GLP-1RA who demonstrate an average ≥0.5 reduction from baseline on the ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period

  14. The percentage of subjects receiving GLP-1RA who achieve a ≥30% reduction from baseline on the ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

    Time frame: Over the last 2 weeks of the 12-week Treatment Period

  15. The change in the ANMS GSCI-DD Total Score and a composite of gastroparesis-related symptoms among subjects receiving GLP-1RA;

    Time frame: over the last 2 weeks of the 12-week Treatment Period, as compared to baseline

  16. All endpoints that are evaluated over the last 2 weeks of the 12-week Treatment period will also be evaluated over the last 6 weeks of the 12-week Treatment period.

    Time frame: Over the last 6 weeks of the 12-week Treatment Period

  17. Change in the PGIS with each dose of CIN-102

    Time frame: From baseline to Week 12

  18. Change in the PGIC with each dose of CIN-102

    Time frame: From baseline to Week 12

07

Study locations

100 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Clinical Research Associates, LLC
    Huntsville, Alabama 35801, United States
  • Phoenix Medical Research Institute, LLC
    Peoria, Arizona 85381, United States
  • Onyx Clinical Research
    Phoenix, Arizona 85381, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology - North Little Rock
    North Little Rock, Arkansas 72117, United States
  • Alliance Research Institute - Bell Gardens
    Bell Gardens, California 90201, United States
  • Hope Clinical Research LLC
    Canoga Park, California 91303, United States
  • Alliance Research Institute, LLC
    Canoga Park, California 91304, United States
  • Erick H. Alayo Medical Corporation
    Chula Vista, California 91910, United States
  • GW Research Inc.
    Chula Vista, California 91910, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • New Hope Research Development
    Corona, California 92882, United States
  • Aurora Care Clinic
    Costa Mesa, California 92627, United States
  • Paragon Rx Clinical
    Garden Grove, California 92840, United States
  • Valley View Wellness and Medical Center - VVCRD
    Garden Grove, California 92845, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 09717, United States
  • Angel City Research
    Los Angeles, California 90010, United States
  • Facey Medical Research
    Mission Hills, California 11333, United States
  • Millennium Clinical Trials
    Thousand Oaks, California 91360, United States
  • Innovative Research of West Florida
    Clearwater, Florida 33756, United States
  • USA and International Research Inc.
    Doral, Florida 33126, United States
  • Advanced Medical Research Group
    Hollywood, Florida 33021, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • ClinCloud LLC
    Maitland, Florida 32751, United States
  • A+ Research Inc
    Miami, Florida 33144, United States
  • International Research Associates LLC - Breton
    Miami, Florida 33183, United States
  • Advanced Research Institute Inc
    New Port Richey, Florida 34653, United States
  • Gastroenterology of Greater Orlando
    Orange City, Florida 32763, United States
  • Tandem Clinical Research - Viera
    Viera, Florida 32940, United States
  • Summit Clinical Research, LLC
    Athens, Georgia 30607, United States
  • Atlanta Center for Gastroenterology P.C.
    Decatur, Georgia 30033, United States
  • Medisphere Medical Research Center
    Evansville, Indiana 47714, United States
  • Lutheran Medical Group
    Fort Wayne, Indiana 46804, United States
  • University of Kansas Medical Center (KUMC)
    Kansas City, Kansas 66160, United States
  • DelRicht Clinical Research - Overland Park
    Overland Park, Kansas 66209, United States
  • Kansas Medical Clinic, P.A.
    Topeka, Kansas 66606, United States
  • Alliance for Multispecialty Research - Wichita West
    Wichita, Kansas 67205, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • DelRicht Clinical Research - Louisville
    Louisville, Kentucky 40205, United States
  • Delta Research Partners
    Bastrop, Louisiana 71201, United States
  • Tandem Clinical Research GI - Houma
    Houma, Louisiana 70363, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Tandem Clinical Research GI - Metairie
    Metairie, Louisiana 70006, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • Clinical Research Institute of Michigan, LLC - Troy
    Troy, Michigan 48098, United States
  • Gastroenterology Associates of Western Michigan
    Wyoming, Michigan 49519, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • St. Charles Clinical Research
    Weldon Spring, Missouri 63304, United States
  • Montana Medical Research, Inc.
    Missoula, Montana 59808, United States
  • American Institute of Medical Research
    Las Vegas, Nevada 89123, United States
  • Digestive Disease Specialists
    Las Vegas, Nevada 89128, United States
  • Allied Health Clinical Research Organization, LLC (AHCRO) - Englewood
    Englewood, New Jersey 07631, United States
  • Allied Health Clinical Research Organization, LLC (AHCRO) - Freehold
    Freehold, New Jersey 07728, United States
  • Allied Health Clinical Research Organization, LLC (AHCRO) - Jackson
    Jackson, New Jersey 08527, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • Smart Medical Research
    Brooklyn, New York 11372, United States
  • Velocity Clinical Research - Syracuse
    East Syracuse, New York 13057, United States
  • Tandem Clinical Research GI- New York
    New York, New York 10033, United States
  • A1 Clinical Network
    Richmond Hill, New York 11418, United States
  • OnSite Clinical Solutions, LLC
    Charlotte, North Carolina 28144, United States
  • Atrium Health - Center for Digestive Health
    Charlotte, North Carolina 28204, United States
  • Research Carolina Elite, LLC
    Denver, North Carolina 28037, United States
  • Coastal Research Institute, LLC
    Fayetteville, North Carolina 28304, United States
  • Cross Creek Medical, PA
    Fayetteville, North Carolina 28304, United States
  • Triad Clinical Trials LLC
    Greensboro, North Carolina 27410, United States
  • Peters Medical Research
    High Point, North Carolina 27260, United States
  • Carolina's GI Research
    Raleigh, North Carolina 27612, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Remington Davis, Inc.
    Columbus, Ohio 43215, United States
  • DelRicht Clinical Research - Cincinnati
    Mason, Ohio 45040, United States
  • Northshore Gastroenterology Research, LLC
    Westlake, Ohio 44145, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • Velocity Clinical Research
    Medford, Oregon 97504, United States
  • Susquehanna Research Group, LLC
    Harrisburg, Pennsylvania 17110, United States
  • Galen Medical Group - Downtown Gastroenterology Location
    Chattanooga, Tennessee 37343, United States
  • WR ClinSearch
    Chattanooga, Tennessee 37421, United States
  • DelRicht Clinical Research - Nashville
    Henderson, Tennessee 37075, United States
  • North Hills Medical Research Inc. (North Hills Familiy Medicine)
    Arlington, Texas 76012, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Texas Gastro Research, LLC
    El Paso, Texas 10908, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Amir A Hassan, MD, PA
    Houston, Texas 77089, United States
  • Care and Cure Clinic
    Houston, Texas 77090, United States
  • Pioneer Research Solutions Inc.
    Houston, Texas 77099, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79905, United States
  • Biopharma Informatic, LLC
    McAllen, Texas 78503, United States
  • DelRicht Clinical Research - McKinney
    McKinney, Texas 75070, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • A1 Clinical Network
    Spring, Texas 77386, United States
  • HP Clinical Research (Val R. Hansen)
    Bountiful, Utah 84010, United States
  • Velocity Clinical Research - Salt Lake City
    West Jordan, Utah 84065, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2025, 31 months.

Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 27, 2023
StartActual
Mar 27, 2023
Primary completionActual
Nov 14, 2025
CompletionActual
Dec 12, 2025
Results delay requested
Nov 3, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and registry dates
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05832151
Lead sponsor
CinDome Pharma, Inc.
Responsible party
Sponsor
First posted
Apr 27, 2023
Start date
Mar 27, 2023
Primary completion
Nov 14, 2025
Completion
Dec 12, 2025
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CIN-102 · Deudomperidone

Start the discussion